Lead Product(s) : xRNA-based Therapy
Therapeutic Area : Nephrology
Study Phase : Discovery Platform
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $150.0 million
Deal Type : Series A Financing
Versant Ventures and Novartis Launch Borealis Biosciences with $150 Million in Funding
Details : The company will use the proceeds to focus on discovering next-generation next-generation xRNA-based medicines for kidney diseases using xRNA technology platform innovation.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
August 22, 2024
Lead Product(s) : xRNA-based Therapy
Therapeutic Area : Nephrology
Highest Development Status : Discovery Platform
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $150.0 million
Deal Type : Series A Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Study Phase : Discovery Platform
Sponsor : Chinook Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration leverages Evotec’s proprietary PanOmics platform, which combines enhanced throughput proteomics, high throughput transcriptomics and cell imaging with PanHunter, Evotec’s unique integrated data analysis platform.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
March 01, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Highest Development Status : Discovery Platform
Sponsor : Chinook Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?